The immunology of renal cell carcinoma
CM Díaz-Montero, BI Rini, JH Finke - Nature Reviews Nephrology, 2020 - nature.com
Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …
Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies
P Makhov, S Joshi, P Ghatalia, A Kutikov… - Molecular cancer …, 2018 - AACR
Renal cell carcinoma (RCC) is the most common form of kidney cancer. It is categorized into
various subtypes, with clear cell RCC (ccRCC) representing about 85% of all RCC tumors …
various subtypes, with clear cell RCC (ccRCC) representing about 85% of all RCC tumors …
[HTML][HTML] N6-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal …
Y Chen, Z Lu, C Qi, C Yu, Y Li, W Huan, R Wang… - Molecular cancer, 2022 - Springer
Background Sunitinib resistance can be classified into primary and secondary resistance.
While accumulating research has indicated several underlying factors contributing to …
While accumulating research has indicated several underlying factors contributing to …
RRM2 regulates sensitivity to sunitinib and PD‐1 blockade in renal cancer by stabilizing ANXA1 and activating the AKT pathway
Renal cell carcinoma (RCC) is a malignant tumor of the kidneys. Approximately 70% of RCC
cases are clear cell renal cell carcinoma with von Hippel–Lindau (VHL) gene mutation and …
cases are clear cell renal cell carcinoma with von Hippel–Lindau (VHL) gene mutation and …
[HTML][HTML] Exosomes in the diagnosis and treatment of renal cell cancer
S Boussios, P Devo, ICA Goodall, K Sirlantzis… - International journal of …, 2023 - mdpi.com
Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer originating from
renal tubular epithelial cells, with clear cell RCC comprising approximately 80% of cases …
renal tubular epithelial cells, with clear cell RCC comprising approximately 80% of cases …
Tumor angiogenesis revisited: regulators and clinical implications
Abstract Since Judah Folkman hypothesized in 1971 that angiogenesis is required for solid
tumor growth, numerous studies have been conducted to unravel the angiogenesis process …
tumor growth, numerous studies have been conducted to unravel the angiogenesis process …
[HTML][HTML] Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
Abstract Background This Phase 1 dose-escalation/expansion study assessed
safety/tolerability of sapanisertib, an oral, highly selective inhibitor of mTORC1/mTORC2, in …
safety/tolerability of sapanisertib, an oral, highly selective inhibitor of mTORC1/mTORC2, in …
[HTML][HTML] Angiocrine endothelium: from physiology to cancer
J Pasquier, P Ghiabi, L Chouchane, K Razzouk… - Journal of translational …, 2020 - Springer
The concept of cancer as a cell-autonomous disease has been challenged by the wealth of
knowledge gathered in the past decades on the importance of tumor microenvironment (TM) …
knowledge gathered in the past decades on the importance of tumor microenvironment (TM) …
TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1
Purpose: Despite the FDA approval of mTOR inhibitors (mTORi) for the treatment of renal
cell carcinoma (RCC), the benefits are relatively modest and the few responders usually …
cell carcinoma (RCC), the benefits are relatively modest and the few responders usually …
Bevacizumab induces acute hypoxia and cancer progression in patients with refractory breast cancer: multimodal functional imaging and multiplex cytokine analysis
S Ueda, T Saeki, A Osaki, T Yamane, I Kuji - Clinical Cancer Research, 2017 - AACR
Purpose: Bevacizumab, an antibody against endothelial growth factor, is a key but
controversial drug in the treatment of metastatic breast cancer. We, therefore, aimed to …
controversial drug in the treatment of metastatic breast cancer. We, therefore, aimed to …